Acción BIOM3 BIOMM S.A.
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate

Otros idiomas Biomm S.A.

Acciones

BIOM3

BRBIOMACNOR2

Mercado cerrado - Sao Paulo
Otros sitios de cotización
 22:07:00 12/06/2024 		Varia. Cinco días. Varia. 1 de enero.
14,21 BRL -1,52 % Gráfico intradía de Biomm S.A. -13,88 % +145,85 %
16/05 Biomm S.A. comunica los resultados del primer trimestre finalizado el 31 de marzo de 2024 CI
17/04 Biocon Limited firma un acuerdo exclusivo de licencia y suministro con Biomm S.A CI

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias: ¡Sea el primero en enterarse y reaccione antes que los mercados!
Inscripción 100% Gratuita
Biomm S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024
Biocon Signs Licensing and Supply Pact with Biomm to Commercialize Generic Ozempic in Brazil
Biocon Limited Signs an Exclusive Licensing and Supply Agreement with Biomm S.A
Biomm S.A. Reports Earnings Results for the Full Year Ended December 31, 2023
Biomm S A : Webcast Presentation 3Q23
Biomm S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Biomm S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Biomm S A : Apresentação de resultados 2T23
Bio-Thera Solutions Expands Partnership with Biomm in Brazil with Addition of BAT2206, A Stelara Biosimilar
Biomm S.A. Reports Earnings Results for the First Quarter Ended March 31, 2023
Biomm S.A. Reports Earnings Results for the Full Year Ended December 31, 2022
Biomm S.A. Reports Earnings Results for the Full Year Ended December 31, 2022
Biomm S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
Biomm S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
Biomm S A : Presentation of 1Q22 Results
Biomm S.A. Reports Earnings Results for the First Quarter Ended March 31, 2022
Biomm S.A. Reports Earnings Results for the Full Year Ended December 31, 2021
Biomm S A : Comunicado ao Mercado
Lupin Enters Partnership to Market Biosimilar Pegfilgrastim in Brazil
CytoDyn : Receives Clearance from Brazil's FDA (ANVISA) to Commence a Pivotal Phase 3 Trial in Critically Ill COVID-19 Patients with IV Administration of Four Doses (700mg/week)
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción BIOM3
  4. Noticias Biomm S.A.
  5. Otros idiomas